Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11839654 Combination therapy

Patent 11839654 was granted and assigned to Eli Lilly and Company on December, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Michael Carl Irizarry0

Mansuo Lu Hayashi0

Hugh Nuthall0

Date of Patent

December 12, 2023

0

Patent Application Number

171416670

Date Filed

January 5, 2021

0

Patent Citations

US Patent 7446180 Conformationally abnormal forms of tau proteins and specific antibodies thereto

0

US Patent 7161060 Transgenic mice comprising a genomic human tau transgene

0

US Patent 7238788 Antibodies to phosphorylated tau, methods of making and methods of use

0

US Patent 7442516 Antibody specific to central nervous system tau protein

0

US Patent 8940272 Human anti-tau antibodies

0

US Patent 8980270 Methods of treating a tauopathy

0

US Patent 8980271 Methods of treating a tauopathy

0

US Patent 9051367 Methods of treating a tauopathy

0

...

Patent Primary Examiner

Kimberly Ballard

0

CPC Code

0

0

0

0

0

0

Patent abstract

The present invention provides a method of treating a tau-mediated cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of an anti-Tau antibody and an effective amount of an OGA inhibitor.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11839654 Combination therapy

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool